Ann: Kazia paxalisib Phase II interim data, page-20

I read an article the other day about small cap companies having the ability to increase the 15% limit on capital raising without shareholder approval. The analyst message did recommend for companies to go early and hard for funds in this challenging financial environment.

Todays Paxalisib interim data presentation by James and management is exceptional and meets my expectation, but I was not expecting the sting in the tail with the existing shareholders having a dilution so soon.

We will learn more on Thursday as to why the urgency for the additional funds. It will likely relate to finalising the deal for Paxalisib to commence the GBM AGILE registration trial. Kazia would need to provide proof that they had the funds in the bank to pay for their agreed ongoing trial expenses.

Regards.